Chronic rejection of concordant aortic xenografts in the hamster-to-rat model. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Chronic rejection of concordant aortic xenografts in the hamster-to-rat model.

Transpl Immunol. 1996 Sep;4(3):192-7. Unique Identifier : AIDSLINE MED/97048617
Scheringa M; Buchner B; de Bruin RW; Geerling RA; Melief MJ; Mulder AH; Schraa EO; Ijzermans JN; Marquet RL; Department of Surgery, Leiden University Hospital, The; Netherlands.


Abstract: Several groups have demonstrated that it is possible to obtain long-term graft survival of concordant xenografts. One of the important questions that remains is whether xenografts are susceptible to chronic rejection. To answer this question we used the aorta transplantation model. One centimetre of hamster aorta was interposed in the abdominal aorta of Lewis rat recipients. The recipients were either untreated (group 1), or treated with 10 mg/kg cyclosporine (CsA), given intramuscularly three times a week (group 2). Rats were sacrificed at day 7, 14, 21, 28, 56 and 84 and the thickness of the intima, the media and the adventitia was measured. Furthermore, the cellularity of the media and the adventitia was assessed by counting the number of nuclei per 0.05 mm2 and immunohistochemistry of the aortic grafts was performed. Graft arteriosclerosis developed in aortic xenografts of both group 1 and group 2. In group 1, intimal lesions were already present from day 21 onwards in all rats, whereas in group 2 they were present only in 33% (2/6) of the rats. At day 84 all the grafts in group 1 were totally occluded, while those in group 2 were still open. The thickness of the media was slightly increased in both groups during the whole observation period, mainly due to edema. Although a few infiltrating macrophages could be seen, the number of nuclei per 0.05 mm2 of the media remained constant during the first 21 days, but declined sharply from day 21 onwards, as a consequence of disappearing myocytes. Thickness of the adventitia in both groups increased after transplantation due to infiltrating macrophages and T cells, reaching a peak at day 14. After day 14 the adventitial thickness in group 1 decreased rapidly to reach values comparable to group 2 from day 28 onwards. In conclusion, graft arteriosclerosis, as a sign of chronic rejection, occurs in concordant aortic xenografts. The lesions in the xenografts develop extremely rapidly, and compared to data from the literature, faster than in aortic allografts. The process of chronic rejection in aortic xenografts can be reduced by CsA.
Keywords: Animal Antibodies/ANALYSIS Aorta, Abdominal Aorta, Thoracic/*TRANSPLANTATION Arteriosclerosis/ETIOLOGY CD4-CD8 Ratio Graft Rejection/ETIOLOGY Hamsters Hemagglutination Tests Immunohistochemistry Macrophages/CYTOLOGY Male Mesocricetus Rats Rats, Inbred Lew Support, Non-U.S. Gov't *Transplantation, Heterologous/IMMUNOLOGY *Transplantation, Heterotopic/ADVERSE EFFECTS JOURNAL ARTICLEKWDanimalantibodies/analysisaorta,abdominalaorta,thoracic/KWDtransplantationarteriosclerosis/etiologycd4-cd8ratiograftrejection/etiologyhamstershemagglutinationtestsimmunohistochemistrymacrophages/cytologymalemesocricetusratsrats,inbredlewsupport,non-uKWDsKWDgov'tKWDtransplantation,heterologous/immunologyKWDtransplantation,heterotopic/adverseeffectsjournalarticle
970228
M9721934

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .